Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC with temozolomide in newly diagnosed glioblastoma
NCT00807027Phase 3Completed
- Sponsor
- GC Cell
- Start
- Dec 2008
- Primary completion
- Oct 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of immuncell-lc in glioblastoma (GBM) (2 arms), sponsored by GC Cell. Primary endpoint: Progression-Free Survival at 46 months. Started Dec 2008; status: completed.
02
Drugs
immuncell-lc
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00807027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807027.